Cargando…

Clinical Outcomes of Molecular Tumor Boards: A Systematic Review

We conducted this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer. METHODS: A systematic search of PubMed was performed to identify studies reporting clinical outcomes in patients with cancer who were reviewed by an MTB....

Descripción completa

Detalles Bibliográficos
Autores principales:	Larson, Kara L., Huang, Bin, Weiss, Heidi L., Hull, Pam, Westgate, Philip M., Miller, Rachel W., Arnold, Susanne M., Kolesar, Jill M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	REVIEW ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277300/ https://www.ncbi.nlm.nih.gov/pubmed/34632252 http://dx.doi.org/10.1200/PO.20.00495

Ejemplares similares

Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial
por: Miller, Rachel W., et al.
Publicado: (2022)

Molecular Tumor Board Review and Improved Overall Survival in Non–Small-Cell Lung Cancer
por: Huang, Bin, et al.
Publicado: (2021)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights
por: Ene, Andre, et al.
Publicado: (2023)

Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in Kentucky and Appalachian Kentucky
por: Chen, Quan, et al.
Publicado: (2023)

Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry
por: Jacob, Aasems, et al.
Publicado: (2021)

Implementation of Nurse Navigation Improves Rate of Molecular Tumor Testing for Ovarian Cancer in a Gynecologic Oncology Practice
por: Rives, Taylor A., et al.
Publicado: (2023)

MTPpilot: An Interactive Software for Visualization of Next-Generation Sequencing Results in Molecular Tumor Boards
por: Kahraman, Abdullah, et al.
Publicado: (2022)

Infantile ZFTA Fusion–Positive Tumor of the Posterior Fossa: Molecular Tumor Board
por: Paulson, Vera A., et al.
Publicado: (2023)

Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards
por: Love, Tara M., et al.
Publicado: (2022)

Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
por: Chauhan, Aman, et al.
Publicado: (2018)

Molecular Tumor Boards: The Next Step towards Precision Therapy in Cancer Care
por: Liu, Angela, et al.
Publicado: (2023)

Patient attrition in Molecular Tumour Boards: a systematic review
por: Frost, Hannah, et al.
Publicado: (2022)

Implementation and utilization of the molecular tumor board to guide precision medicine
por: Harada, Shuko, et al.
Publicado: (2017)

Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy
por: Harbin, Laura M., et al.
Publicado: (2022)

SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer
por: Harbin, Laura M., et al.
Publicado: (2023)

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
por: Danesi, R., et al.
Publicado: (2021)

Lessons learned: the first consecutive 1000 patients of the CCCMunich(LMU) Molecular Tumor Board
por: Heinrich, Kathrin, et al.
Publicado: (2022)

Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer
por: Behel, Vichitra, et al.
Publicado: (2022)

Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors
por: Wang, Peng, et al.
Publicado: (2018)

Implementing the Single Institutional Review Board Model: Lessons from the Undiagnosed Diseases Network
por: Splinter, Kimberly, et al.
Publicado: (2017)

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich(LMU) Molecular Tumor Board
por: Dorman, Klara, et al.
Publicado: (2023)

DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden
por: Riggs, McKayla J., et al.
Publicado: (2020)

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy
por: Louie, Bryan H., et al.
Publicado: (2022)

hPG(80) (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors
por: Chauhan, Aman, et al.
Publicado: (2022)

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations
por: Koopman, Bart, et al.
Publicado: (2020)

Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine
por: Stoeklé, Henri-Corto, et al.
Publicado: (2017)

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
por: Crimini, Edoardo, et al.
Publicado: (2022)

MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
por: Hutchcraft, Megan L., et al.
Publicado: (2021)

Prioritization of family member sequencing for the detection of rare variants
por: Sippy, Rachel, et al.
Publicado: (2016)

Editorial: Anticancer Potential of Artemisia annua
por: Kolesar, Jill M., et al.
Publicado: (2022)

Gynecologic large cell neuroendocrine carcinoma: A review
por: Burkeen, Grant, et al.
Publicado: (2020)

Successful implementation of an international desmoid tumor virtual tumor board: A novel platform for the management of rare tumors
por: Weiss, Aaron R, et al.
Publicado: (2020)

Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
por: Gorski, Justin W., et al.
Publicado: (2021)

Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations
por: Willemsen, Annelieke E. C. A. B., et al.
Publicado: (2019)

Implementing precision oncology for sarcoma patients: the CCC(LMU)molecular tumor board experience
por: Berclaz, Luc M., et al.
Publicado: (2023)

A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients
por: Pishvaian, Michael J, et al.
Publicado: (2019)

Proceedings of tumor board meeting
por: Bhatnagar, Sushmita, et al.
Publicado: (2012)

Software-Tool Support for Collaborative, Virtual, Multi-Site Molecular Tumor Boards
por: Schapranow, Matthieu-P., et al.
Publicado: (2023)

A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence
por: Sunami, Kuniko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7rui9v0m6u5l1rsqerfrdpg6da